Business Description
Rohto Pharmaceutical Co Ltd
ISIN : JP3982400008
Total Employee Number:
10,898Description
Rohto Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of health and beauty care products. The company operates through four reportable segments: Japan, America, Europe, and Asia. Each segment manufactures and sells products related to eye care (such as eye drops and eyewash), skin care (including dermatological medications, lip balm, sunscreen, and functional cosmetics), oral medication (such as gastrointestinal and herbal medicines, and supplements), and other products such as in-vitro diagnostic reagents. It generates the majority of its revenue from Japan.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.44 | |||||
Equity-to-Asset | 0.62 | |||||
Debt-to-Equity | 0.2 | |||||
Debt-to-EBITDA | 0.92 | |||||
Interest Coverage | 32.03 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 4.1 | |||||
Beneish M-Score | -2.47 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 11.8 | |||||
3-Year EBITDA Growth Rate | 14.5 | |||||
3-Year EPS without NRI Growth Rate | 7.9 | |||||
3-Year FCF Growth Rate | -0.2 | |||||
3-Year Book Growth Rate | 13.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 3.99 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 5.32 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.04 | |||||
Quick Ratio | 1.48 | |||||
Cash Ratio | 0.74 | |||||
Days Inventory | 154.53 | |||||
Days Sales Outstanding | 52.59 | |||||
Days Payable | 49.95 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Dividend Growth Rate | 27.9 | |||||
3-Year Average Share Buyback Ratio | 0.3 | |||||
Shareholder Yield % | 0.91 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 56.06 | |||||
Operating Margin % | 11.96 | |||||
Net Margin % | 9.96 | |||||
EBITDA Margin % | 19.05 | |||||
FCF Margin % | 5.81 | |||||
OCF Margin % | 12.89 | |||||
ROE % | 12.28 | |||||
ROA % | 7.6 | |||||
ROIC % | 8.75 | |||||
3-Year ROIIC % | 2.47 | |||||
ROC (Joel Greenblatt) % | 32.01 | |||||
ROCE % | 13.8 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 17.05 | |||||
Forward PE Ratio | 18.2 | |||||
PE Ratio without NRI | 16.64 | |||||
Shiller PE Ratio | 25.79 | |||||
PEG Ratio | 1.02 | |||||
PS Ratio | 1.67 | |||||
PB Ratio | 1.85 | |||||
Price-to-Tangible-Book | 2.57 | |||||
Price-to-Free-Cash-Flow | 27.12 | |||||
Price-to-Operating-Cash-Flow | 12.22 | |||||
EV-to-EBIT | 11.16 | |||||
EV-to-EBITDA | 8.19 | |||||
EV-to-Revenue | 1.56 | |||||
EV-to-FCF | 25.61 | |||||
Price-to-GF-Value | 0.71 | |||||
Price-to-Projected-FCF | 1.12 | |||||
Price-to-DCF (Earnings Based) | 0.61 | |||||
Price-to-DCF (FCF Based) | 1.35 | |||||
Price-to-Median-PS-Value | 0.83 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.8 | |||||
Price-to-Graham-Number | 1.38 | |||||
| Price-to-Net-Current-Asset-Value | 10.12 | |||||
Earnings Yield (Greenblatt) % | 8.96 | |||||
FCF Yield % | 3.96 | |||||
Forward Rate of Return (Yacktman) % | 19.79 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Rohto Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil MXN) | 41,519.967 | ||
| EPS (TTM) (MXN) | 17.784 | ||
| Beta | 0.0022 | ||
| 3-Year Sharpe Ratio | -4.15 | ||
| 3-Year Sortino Ratio | -2.67 | ||
| Volatility % | 1.2 | ||
| 14-Day RSI | - | ||
| 14-Day ATR (MXN) | - | ||
| 20-Day SMA (MXN) | 305.75 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (MXN) | 305.75 - 305.75 | ||
| Shares Outstanding (Mil) | 225.96 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Rohto Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Rohto Pharmaceutical Co Ltd Stock Events
| Event | Date | Price (MXN) | ||
|---|---|---|---|---|
| JPY 25.000000 Cash Dividend | 2026-09-30 | In 70 days | ||
| JPY 25.000000 Cash Dividend | 2026-03-31 | 305.75 (+0.00%) | ||
| JPY 21.000000 Cash Dividend | 2025-09-30 | 305.75 (+0.00%) | ||
| JPY 20.000000 Cash Dividend | 2025-03-31 | 305.75 (+0.00%) | ||
| JPY 16.000000 Cash Dividend | 2024-09-30 | 320.18 (+0.00%) | ||
| 2:1 Stock Split | 2022-12-29 | 319.78 (+0.00%) |
Show
Entries
Rohto Pharmaceutical Co Ltd Frequently Asked Questions
What is Rohto Pharmaceutical Co Ltd(MEX:4527N)'s stock price today?
The current price of MEX:4527N is MXN305.75. The 52 week high of MEX:4527N is MXN305.75 and 52 week low is MXN305.75.
When is next earnings date of Rohto Pharmaceutical Co Ltd(MEX:4527N)?
The next earnings date of Rohto Pharmaceutical Co Ltd(MEX:4527N) is .
Does Rohto Pharmaceutical Co Ltd(MEX:4527N) pay dividends? If so, how much?
Rohto Pharmaceutical Co Ltd(MEX:4527N) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Rohto Pharmaceutical Co Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers